Plenn Eion, Amin Dylan, Henry Jonathan, Leavitt Gabrielle, Walker Jason, Soleymani Taraneh
Penn State College of Medicine Hershey Pennsylvania USA.
St. George's University School of Medicine West Indies Grenada.
Obes Sci Pract. 2025 Aug 6;11(4):e70085. doi: 10.1002/osp4.70085. eCollection 2025 Aug.
Semaglutide 2.4 mg (Wegovy) is the first second-generation anti-obesity medication approved by the FDA for long-term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first-generation anti-obesity medications and amid ongoing national shortages, understanding the real-world experiences of individuals using semaglutide 2.4 mg is crucial. This qualitative study aims to explore the narratives of individuals using semaglutide 2.4 mg for weight management, as expressed in Reddit posts.
One thousand posts from the r/WegovyWeightLoss subreddit between October 10, 2022, and October 6, 2023, were retrospectively analyzed. After excluding irrelevant posts, 660 posts were included in the analysis. A codebook was collaboratively developed and data was coded using qualitative software. Themes were finalized and reviewed.
Seven themes were identified from the analysis: medication efficacy (29.4% of coded posts), psychosocial impact of weight loss (22.8%), side effects management (13.3%), barriers to access (10.7%), lifestyle modification (10.2%), support and community (9.2%), and stigma surrounding use of semaglutide 2.4 mg for weight loss (4.4%).
This qualitative analysis of Reddit posts provides valuable insights into the real-world experiences of individuals using semaglutide 2.4 mg for weight management. By understanding these user experiences, healthcare providers can better tailor obesity treatment plans and enhance patient-centered care for those using second-generation anti-obesity medications like semaglutide 2.4 mg.
司美格鲁肽2.4毫克（Wegovy）是美国食品药品监督管理局（FDA）批准用于长期肥胖治疗的首款第二代抗肥胖药物。鉴于司美格鲁肽2.4毫克与第一代抗肥胖药物相比的有效性以及全国范围内持续的短缺情况，了解使用司美格鲁肽2.4毫克的个人的真实世界经历至关重要。这项定性研究旨在探索在Reddit帖子中表达的使用司美格鲁肽2.4毫克进行体重管理的个人叙述。
回顾性分析了2022年10月10日至2023年10月6日期间r/WegovyWeightLoss子版块的1000篇帖子。在排除无关帖子后，660篇帖子纳入分析。共同制定了编码手册，并使用定性软件对数据进行编码。主题最终确定并进行了审查。
分析确定了七个主题：药物疗效（编码帖子的29.4%）、体重减轻的心理社会影响（22.8%）、副作用管理（13.3%）、获取障碍（10.7%）、生活方式改变（10.2%）、支持与社区（9.2%）以及围绕使用司美格鲁肽2.4毫克减肥的污名（4.4%）。
这项对Reddit帖子的定性分析为使用司美格鲁肽2.4毫克进行体重管理的个人的真实世界经历提供了有价值的见解。通过了解这些用户体验，医疗保健提供者可以更好地调整肥胖治疗计划，并加强对使用司美格鲁肽2.4毫克等第二代抗肥胖药物的患者的以患者为中心的护理。
